Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

Overview of attention for article published in Breast Cancer Research and Treatment, January 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 65 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 12,673 followers.

Eficacia y seguridad de dasatinib con trastuzumab y paclitaxel en el cáncer de mama metastásico HER2 positivo de primera línea: resultados del estudio de fase II GEICAM. #farmacia #medicina #cancer #ciencia #oncologia #hospital https://t.co/klulJwUZDt http

26 Mar 2019

Reply Repost Favourite

《短報》【HER2陽性乳がん：一次治療】「ハーセプチン＋パクリタキセル」に慢性骨髄性白血病の治療薬として承認されている「スプリセル」を上乗せするPhase2試験の結果。奏効率：79.3％、無病生存期間：23.9ヵ月。〔Breast Cancer Res Treat〕 https://t.co/BaO60S82pO https://t.co/BaO60S82pO

08 Jan 2019

Reply Repost Favourite